Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 4
Submit an article Journal homepage
443
Views
8
CrossRef citations to date
0
Altmetric
Letter to the Editor

Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia

Margaret Nieborowska-SkorskaDepartment of Microbiology and Immunology and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA; View further author information
,
Silvia MaifredeDepartment of Microbiology and Immunology and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA; View further author information
,
Min YeTemple University School of Pharmacy, Moulder Center for Drug Discovery Research, Philadelphia, PA, USA; View further author information
,
Monika TomaDepartment of Microbiology and Immunology and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA; ;Laboratory of Medical Genetics Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland; View further author information
,
Elizabeth HewlettTemple University School of Pharmacy, Moulder Center for Drug Discovery Research, Philadelphia, PA, USA; View further author information
,
John GordonTemple University School of Pharmacy, Moulder Center for Drug Discovery Research, Philadelphia, PA, USA; View further author information
,
Bac Viet LeDepartment of Microbiology and Immunology and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA; ;Laboratory of Cytometry, Nencki Institute of Experimental Biology, Warsaw, Poland; View further author information
,
Tomasz SliwinskiLaboratory of Medical Genetics Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland; View further author information
,
Huaqing ZhaoDepartment of Clinical Sciences Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA; View further author information
,
Katarzyna PiwockaLaboratory of Cytometry, Nencki Institute of Experimental Biology, Warsaw, Poland; View further author information
,
Peter ValentDepartment of Internal Medicine I Division of Hematology & Hemostaseology and Ludwig-Boltzmann Cluster Oncology, Medical University of Vienna, Austria, Vienna; View further author information
,
Alexei V. TulinDepartment of Biomedical Sciences School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, USAView further author information
,
Wayne ChildersTemple University School of Pharmacy, Moulder Center for Drug Discovery Research, Philadelphia, PA, USA; View further author information
&
Tomasz SkorskiDepartment of Microbiology and Immunology and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA; Correspondence[email protected]
View further author information
 show all
Pages 1098-1101 | Received 06 Jun 2018, Accepted 01 Sep 2018, Published online: 02 Oct 2018
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2018.1520988.

Additional information

Funding

This work was supported by NHI/NCI 1R01 CA186238 to T.S. and Department of Deference PC160049 and the NIH R03 CA212566 to A.V.T. M.T. was supported by the Kosciuszko Foundation Scholarship for 2017/2018. B.V.L has been supported by the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement no 665735 and by the funding from Polish Ministry of Science and Higher Education funds for the implementation of international projects, 2016–2020. P.V. was supported by the Austrian Science Fund, grant F4704-B20.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies
Source: MDPI AG

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.